- Home
- NDMO vs PHAR Comparison
NDMO vs PHAR Comparison
Compare NDMO & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NDMO | PHAR |
|---|---|---|
| Founded | 2019 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 622.4M | 1.1B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NDMO | PHAR |
|---|---|---|
| Price | $9.98 | $17.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $38.00 |
| AVG Volume (30 Days) | ★ 218.6K | 23.0K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 6.75% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.00 |
| Revenue | N/A | ★ $362,274,000.00 |
| Revenue This Year | N/A | $25.19 |
| Revenue Next Year | N/A | $4.47 |
| P/E Ratio | ★ N/A | $3,089.47 |
| Revenue Growth | N/A | ★ 26.78 |
| 52 Week Low | $8.99 | $7.50 |
| 52 Week High | $11.24 | $18.12 |
Technical Indicators
Market Signals| Indicator | NDMO | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 28.24 | 54.31 |
| Support Level | $10.03 | $16.15 |
| Resistance Level | $10.22 | $17.00 |
| Average True Range (ATR) | 0.16 | 0.76 |
| MACD | -0.03 | -0.06 |
| Stochastic Oscillator | 5.71 | 53.81 |
Price Performance
Historical ComparisonAbout NDMO Nuveen Dynamic Municipal Opportunities Fund of Beneficial Interest
Nuveen Dynamic Municipal Opportunities is a closed-end management investment company. Its investment objective is to seek total return through income exempt from regular federal income taxes and capital appreciation. A majority of its investments are made in municipal securities, the income from which is exempted from regular federal income taxes.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.